Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

742results about "Polymorphism uses" patented technology

Compositions and methods for treating cancer

PCT designated stage expiredWO2025054270A1Organic active ingredientsPolymorphism uses
The disclosure is directed to methods for treating a cancer in a subject in need thereof by administering to the subject a bifunctional short hairpin (shRNA) molecule capable of inhibiting the expression of at least one mutated KRAS gene and at least one KRAS inhibitor.
Owner:GRADALIS INC

Oligonucleotide compositions and methods thereof

Among other things, the present disclosure provides oligonucleotides, compositions, and methods thereof. Among other things, the present disclosure encompasses the recognition that structural elements of oligonucleotides, such as base sequence, chemical modifications (e.g., modifications of sugar, base, and / or internucleotidic linkages) or patterns thereof, conjugation with additional chemical moieties, and / or stereochemistry [e.g., stereochemistry of backbone chiral centers (chiral internucleotidic linkages)], and / or patterns thereof, can have significant impact on oligonucleotide properties and activities, e.g., knockdown ability, stability, delivery, etc. In some embodiments, the oligonucleotides decrease the expression, activity and / or level of a C9orf72 gene, including but not limited to, one comprising a repeat expansion, or a gene product thereof. In some embodiments, the present disclosure provides methods for treatment of diseases using provided oligonucleotide compositions, for example, in treatment of C9orf72-related disorders.
Owner:WAVE LIFE SCI LTD

Compositions for treating cancer with KRAS mutations and uses thereof

The present application provides guide RNAs and genome-editing complexes or nanoparticles that are useful for specifically targeting a mutated KRAS. Exemplary genome-editing complexes or nanoparticles comprise cell-penetrating peptides, and optionally a DNA nuclease (such as Cas9) or a polynucleotide encoding the DNA nuclease.
Owner:AADIGEN LLC

Polynucleotides, pharmaceutical compositions and uses thereof

The invention discloses polynucleotide, a pharmaceutical composition and application of the polynucleotide. In the application, a plurality of polynucleotide sequences targeting the 3'untranslated region of the nuclear fiber layer protein A mutant mRNA are newly designed, the expression level of the nuclear fiber layer protein A mutant (such as premature protein) can be reduced in the Lamin AmRNA stage, and meanwhile, the normal transcription of Lamin C is not influenced, so that the toxic and side effects are lower; the compound has a wide prospect in the aspect of preventing or treating diseases (especially progeria) related to mutation of the nuclear fiber layer protein A.
Owner:LIANGZHU LAB

Stereospecific linkages in RNA editing oligonucleotides

The invention relates to editing oligonucleotides (EONs) that carry stereospecific phosphorothioate internucleotide linkage modifications at specified positions and that do not carry such modifications on positions that would lower RNA editing efficiency. The selection of positions that should or should not carry a phosphorothioate Rp and / or Sp configuration modification is based on computational modelling that revealed incompatibilities of the stereospecific linkages with the intermolecular oxygen-mediated hydrogen bond network.
Owner:PROQR THERAPEUTICS II BV

Chemically modified single-stranded rna-editing oligonucleotides

The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA sequence in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a non-complementary nucleotide in a position opposite to the nucleotide to be edited in the target RNA sequence.
Owner:PROQR THERAPEUTICS II BV

Site-directed editing of RNA

The present disclosure, in some aspects, relates to antisense oligonucleotides (ASO) for use in the prevention or treatment of a disease or a condition associated with low- density lipoprotein (LDL) in a subject. In some embodiments, the ASO effects site-directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous low-density lipoprotein receptor (LDLR) gene such that: a) the modified LDLR protein has: (i) reduced binding to the inducible degrader of the LDLR protein (IDOL); (ii) increased stability; (iii) improved resistance to IDOL-mediated degradation; (iv) increased LDLR protein expression; and / or (v) increased activity or function to take up LDL; and / or b) editing of the 3'-untranslated region (UTR) of the target RNA leads to an increase in LDLR protein expression and / or stability.
Owner:AIRNA CORPORATION +5

Gene editing systems, compositions, and methods for treatment of vexas syndrome

The present disclosure describes gene editing systems and therapeutics for use in treating VEXAS syndrome. In particular, the disclosure describes lipid nanoparticles that enhance the targeted delivery of gene editing systems and therapeutics to blood cell progenitor cells, enabling treatment of VEXAS syndrome, in vivo or ex vivo.
Owner:RENAGADE THERAPEUTICS MANAGEMENT INC

Compositions and methods for editing beta-globin for treatment of hemaglobinopathies

The disclosure features systems and methods for correcting a mutation in the human beta-globin (HBB) gene in a cell or population of cells. The disclosure also features methods of increasing repair of a DNA double stranded break (DSB) in an HBB gene by the homology-directed repair (HDR) pathway. The disclosure also features compositions for use in the methods.
Owner:VERTEX PHARMACEUTICALS INC

Oligonucleotides for inducing paternal UBE3A expression

The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD1091B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
Owner:OHB PEDIATRICS LTD

Allele-specific knockdown of gene expression

Described herein are methods of inhibiting an allele that contains a mutation in a cell (e.g., treating a subject with an allele that contains a mutation). The method includes delivering to the cell an antisense oligonucleotide that targets a variant allele that is in cis with the mutation (e.g., the mutation is a gain of function mutation or a dominant negative mutation), wherein the cell or subject is heterozygous for the target variant, and the antisense molecule is effective at knocking down expression the target variant allele (e.g., effective at preventing, treating, or ameliorating at least one symptom associated with the mutation). Also described herein are methods of haplotyping a cell or subject, and antisense oligonucleotides that target mutant superoxide dismutase 1 (SOD1) and other genes.
Owner:UNIV OF MASSACHUSETTS

Compositions and methods for homology-directed repair gene modification

Provided herein are methods and compositions for genetically engineering a cell (e.g., a hematopoietic cell) using CRISPR / Cas systems and homology-directed repair, genetically engineered cells produced by such methods, and methods involving administering such genetically engineered cells to a subject, such as a subject having a genetic disease.
Owner:SYZYGYMED INC

RNAi TARGETING KIF1A MISSENSE MUTATIONS FOR TREATMENT OF KIF1A ASSOCIATED NEUROLOGICAL DISORDER

RNAi involving siRNA, shRNA, or antisense oligonucleotides (ASO) are provided that reduce expression of toxic KIF1A alleles thereby reducing production of mutant KIF1A for treatment of KAND. Also provided are RNA-targeting oligonucleotides that reduce expression of toxic KIF1A alleles herein incorporate sequences that target common benign single nucleotide polymorphisms (SNPs) which are present in cis with one or more causative KIF1A mutations.
Owner:OVID THERAPEUTICS INC

Oligonucleotide compositions and methods thereof

Among other things, the present disclosure provides designed oligonucleotides and compositions thereof. In some embodiments, oligonucleotides and compositions of the present disclosure can provide high levels of adenosine editing. In some embodiments, oligonucleotides and compositions of the present disclosure are useful for treating various conditions, disorders or diseases, e.g., alpha-1 antitrypsin deficiency. In some embodiments, the present disclosure provides methods for treating various conditions, disorders or diseases that can benefit from adenosine editing.
Owner:WAVE LIFE SCI LTD

Methods of preventing or treating liver disease

Methods of preventing or treating liver disease in a subject characterised as having a PNPLA3- 148M protein variant are provided. The methods include administering to the subject an oligonucleotide or a DNA molecule encoding an oligonucleotide, wherein the oligonucleotide is capable of effecting ADAR-mediated editing of a polynucleotide encoding the PNPLA3-148M protein variant, and wherein the polynucleotide encoding the PNPLA3-148M protein variant undergoes ADAR-mediated editing at a codon encoding the methionine at position 148 such that the polynucleotide encodes a PNPLA3-148V protein variant. The disclosure also provides methods of editing a target ribonucleic acid (RNA) molecule encoding a PNPLA3-148M protein variant and methods of restoring the function of the PNPLA3 protein in a subject characterised as having the PNPLA3-148M protein variant.
Owner:GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO 3) LIMITED

Compositions and methods to modulate idiopathic pulmonary fibrotic associated long noncoding rnas

PCT designated stage expiredWO2025068766A2Polymorphism usesMicrobiological testing/measurement
Disclosed herein are modulators of a long non-coding RNA (IncRNA), wherein an expression of the IncRNA is associated with idiopathic pulmonary fibrosis. Further provided herein are methods of treating idiopathic pulmonary fibrosis a subject in need thereof. Also, provided herein are methods of predicting severity and progression of idiopathic pulmonary fibrosis based on expression of the IncRNAs described herein.
Owner:HAYA THERAPEUTICS SA

Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants

Streptococcus pyogenes Cas9 (SpCas9) variants with relaxed PAM requirements capable of high-resolution editing for various applications, and methods of use thereof.
Owner:THE GENERAL HOSPITAL CORP

Compositions and methods for treating TDP-43 proteinopathy

The present disclosure relates to the use of UNC13A cryptic exon splice variant specific inhibitors for methods of reducing expression of a UNC13A cryptic exon splice variant in a cell, reducing phosphorylated TAR-DNA binding protein-43 (TDP-43) in a cell, treating TAR-DNA binding protein-43 (TDP-43) proteinopathy in a subject, or treating a subject has been identified as having a UNC13A mutation in intron 20-21 of UNC13A. Antisense oligonucleotides directed against UNC13A cryptic splice variant are also contemplated.
Owner:TRACE NEUROSCIENCE INC

Methods of substituting pathogenic amino acids using programmable base editor systems

Provided herein are compositions and methods of using base editors comprising a polynucleotide programmable nucleotide binding domain and a nucleobase editing domain in conjunction with a guide polynucleotide. Also provided herein are base editor systems for editing nucleobases of target nucleotide sequences.
Owner:BEAM THERAPEUTICS INC

Oligonucleotides for inducing paternal UBE3a expression

The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.
Owner:OHB PEDIATRICS LTD

Modified oligonucleotides with increased stability

To provide a metabolically stable phosphorothioate-modified RNA.SOLUTION: The present invention provides a modified oligonucleotide, having a 5' end and a 3' end, and comprising a sense strand and an antisense strand complementary to a target, and at least one modified intersubunit linkage of Formula I, where at least one modified oligonucleotide is incorporated into the antisense strand or sense strand of an siRNA.SELECTED DRAWING: None
Owner:UNIV OF MASSACHUSETTS

Oligonucleotide compositions and methods thereof

Among other tilings, the present disclosure provides various technologies including chirally controlled oligonucleotide compositions and technologies for manufacturing and using such oligonucleotide compositions. In some embodiments, the present disclosure provides technologies useful for allele-specific knockdown of mutant Huntingtin transcripts. In some embodiments, the present disclosure provides technologies usefill for reducing the expression, level, amount, and / or activity of mutant Huntingtin transcripts or products thereof. In some embodiments, the present disclosure provides methods for treating Huntington's disease.
Owner:WAVE LIFE SCI LTD +22

A platform for using iPSC-derived cardiomyocytes carrying gene variants as models of cardiac disease and drug response

The present disclosure is in the field of cardiac disease.For example, the present disclosure provides a new platform that includes iPSC and cardiomyocyte carrying one or more gene mutations, and a model for studying the effect of those gene mutations on cardiomyocyte and on drug toxicity.This platform is herein identified as PREDICT PLATFORM.
Owner:SRI INTERNATIONAL

Allele specific editing to treat FUS-induced neurodegeneration

Methods and compositions are described herein that are useful to treat pathological mutation in the fused in sarcoma (FUS) gene. A number of FUS mutations are correlated with neurodegenerative conditions such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The methods and compositions can target and reduce or eliminate such FUS mutations.
Owner:THE J DAVID GLADSTONE INSTITUTES

Compositions and methods for treating glycogen storage disease type 1A

The present invention provides compositions comprising novel adenosine base editors (e.g., ABE8) with increased efficiency, and methods of using base editors comprising adenosine deaminase variants to alter mutations associated with glycogen storage disease type 1a (GSD1a).
Owner:BEAM THERAPEUTICS INC